Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23373592 | 1.00 | RNPEP (0.35) | RNPEPNAALAD2ALDH1A1LMNAMAPT | |
| SCHEMBL20980751 | 0.83 | NAALAD2 (0.36) | NAALAD2ALDH1A1HDAC1FPR2 | |
| SCHEMBL25761623 | 0.83 | NAALAD2 (0.36) | NAALAD2ALDH1A1HDAC1FPR2 | |
| SCHEMBL19764845 | 0.83 | NAALAD2 (0.36) | NAALAD2ALDH1A1HDAC1FPR2 | |
| SCHEMBL21507151 | 0.71 | CYP2D6 (0.41) | RNPEPNAALAD2ALDH1A1MAPTTDP1 | |
| SCHEMBL24613313 | 0.71 | CYP2D6 (0.41) | RNPEPNAALAD2ALDH1A1MAPTTDP1 | |
| SCHEMBL20980675 | 0.70 | — | — | |
| SCHEMBL10261275 | 0.70 | — | — | |
| SCHEMBL27587987 | 0.69 | MMP1 (0.34) | NAALAD2ALDH1A1 | |
| SCHEMBL26702911 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | RNPEP 1064/4885NAALAD2 1983/4885ALDH1A1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.